…
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -0.06M | -75.22M | -137.18M | -39.96M | -14.16M |
| Net income | -0.06M | -75.21M | -138.01M | -35.38M | -14.22M |
| Selling general administrative | 22.39M | 28.35M | 51.83M | 12.22M | 3.00M |
| Selling and marketing expenses | 22.36M | - | - | - | - |
| Gross profit | -2.23M | 0.00M | -1.87M | 0.51M | 0.00M |
| Reconciled depreciation | 2.32M | 1.68M | 1.10M | 0.72M | 0.11M |
| Ebit | -56.24M | -75.98M | -125.08M | -32.28M | -13.66M |
| Ebitda | -54.00M | -73.04M | -123.96M | -37.33M | -13.58M |
| Depreciation and amortization | 2.23M | 2.94M | 1.11M | -5.04M | 0.08M |
| Non operating income net other | - | 0.95M | -12.10M | - | - |
| Operating income | -58.28M | -75.98M | -125.08M | -32.28M | -13.66M |
| Other operating expenses | 58.28M | 75.98M | 125.14M | 32.84M | 13.66M |
| Interest expense | 0.70M | 0.51M | 0.84M | 1.18M | 0.43M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.06M |
| Interest income | 2.29M | 1.26M | 0.01M | - | - |
| Net interest income | 1.53M | 0.74M | -0.83M | -1.18M | -0.43M |
| Income tax expense | -0.06M | -0.01M | 0.84M | -4.58M | 0.06M |
| Total revenue | 0.00M | 0.00M | 0.07M | 0.56M | 0.00M |
| Total operating expenses | 56.05M | 75.98M | 123.20M | 32.79M | 13.66M |
| Cost of revenue | 2.23M | 0.00M | 1.94M | 0.05M | 0.00M |
| Total other income expense net | 1.35M | 0.76M | -12.10M | -7.67M | -0.50M |
| Net income from continuing ops | -66.00M | -75.22M | -137.18M | -39.96M | -14.22M |
| Net income applicable to common shares | - | -75.22M | -137.18M | -39.96M | -14.22M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 44.31M | 106.40M | 166.67M | 50.14M | 1.59M |
| Other current assets | 2.42M | 0.52M | 0.34M | 0.83M | 0.66M |
| Total liab | 30.90M | 44.22M | 38.05M | 137.52M | 50.11M |
| Total stockholder equity | 13.41M | 62.18M | 128.62M | -87.38M | -48.51M |
| Deferred long term liab | - | - | - | 2.25M | - |
| Other current liab | 13.92M | 24.14M | 23.93M | 8.61M | 5.41M |
| Common stock | 0.28M | 0.28M | 0.28M | 0.27M | 0.27M |
| Capital stock | 0.28M | 0.28M | 0.28M | 0.27M | 0.27M |
| Retained earnings | -361.64M | -304.70M | -229.48M | -92.31M | -52.35M |
| Other liab | - | - | 0.24M | 27.11M | 2.26M |
| Other assets | 0.00M | - | 0.37M | 2.31M | - |
| Cash | 4.93M | 33.48M | 144.88M | 31.14M | 0.48M |
| Total current liabilities | 17.61M | 30.94M | 27.49M | 37.22M | 19.88M |
| Net debt | 10.24M | -18.93M | -134.19M | 7.16M | 13.86M |
| Short term debt | 1.91M | 1.50M | 0.38M | 27.59M | 13.19M |
| Short long term debt | 1.91M | 1.50M | 0.38M | 27.59M | 13.19M |
| Short long term debt total | 15.17M | 14.55M | 10.70M | 38.30M | 14.33M |
| Other stockholder equity | 374.76M | 366.80M | 357.82M | 4.66M | 3.57M |
| Property plant equipment | - | 12.51M | 12.17M | 12.16M | 0.16M |
| Total current assets | 33.23M | 93.89M | 154.13M | 35.67M | 1.44M |
| Net tangible assets | - | 62.18M | 128.62M | -87.38M | -48.51M |
| Short term investments | 25.46M | 53.35M | - | - | - |
| Net receivables | 0.41M | 0.41M | 0.39M | 0.39M | 0.30M |
| Long term debt | 13.26M | 9.93M | 10.32M | 10.70M | 1.12M |
| Inventory | - | 6.12M | 8.51M | 3.31M | - |
| Accounts payable | 1.78M | 5.29M | 3.19M | 1.02M | 1.28M |
| Accumulated other comprehensive income | 0.01M | -0.20M | - | - | - |
| Common stock total equity | - | 0.28M | 0.28M | - | - |
| Retained earnings total equity | - | -304.70M | -229.48M | - | - |
| Non currrent assets other | - | - | 0.17M | 2.31M | - |
| Non current assets total | 11.08M | 12.51M | 12.54M | 14.47M | 0.16M |
| Capital lease obligations | - | - | - | 0.01M | 0.03M |
| Long term debt total | - | 9.93M | 10.32M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 56.46M | -54.39M | -1.32M | -1.48M | -52.53M |
| Change to liabilities | - | 4.44M | 13.13M | -0.27M | -0.45M |
| Total cashflows from investing activities | 28.84M | -54.39M | -1.32M | -1.48M | -1.48M |
| Net borrowings | -1.59M | -0.43M | -0.81M | 6.59M | 11.12M |
| Total cash from financing activities | -1.14M | -0.17M | 196.17M | 66.11M | 11.14M |
| Change to operating activities | - | 7.72M | 10.68M | -2.50M | 0.60M |
| Net income | -56.93M | -75.22M | -137.18M | -39.96M | -14.22M |
| Change in cash | -29.53M | -110.49M | 113.86M | 30.72M | -1.13M |
| Begin period cash flow | 34.57M | 145.06M | 31.20M | 0.48M | 1.60M |
| End period cash flow | 5.04M | 34.57M | 145.06M | 31.20M | 0.48M |
| Total cash from operating activities | -57.24M | -55.93M | -80.99M | -33.91M | -12.27M |
| Issuance of capital stock | - | 0.00M | 193.87M | 20.42M | 0.00M |
| Depreciation | 2.23M | 1.68M | 1.10M | 0.72M | 0.11M |
| Other cashflows from investing activities | - | -52.53M | - | - | - |
| Change to inventory | - | - | 8.43M | -0.24M | - |
| Change to account receivables | -0.00M | 0.00M | 0.03M | -0.03M | -0.03M |
| Sale purchase of stock | - | 0.26M | 59.85M | -0.04M | 0.00M |
| Other cashflows from financing activities | 0.00M | 0.26M | 127.86M | 71.85M | 11.14M |
| Change to netincome | - | 8.71M | 3.16M | 8.01M | 1.69M |
| Capital expenditures | 0.80M | 1.87M | 1.32M | 1.48M | 1.48M |
| Change receivables | - | -0.02M | - | - | - |
| Cash flows other operating | - | 4.42M | 38.53M | - | - |
| Cash and cash equivalents changes | - | -110.49M | -16.20M | - | - |
| Change in working capital | -8.54M | 9.82M | 12.88M | -2.79M | 0.16M |
| Stock based compensation | 0.01M | 8.71M | 30.41M | 1.01M | 1.23M |
| Other non cash items | 6.00M | -0.93M | 3.21M | 6.45M | 0.46M |
| Free cash flow | -58.04M | -57.79M | -82.31M | -35.39M | -12.27M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VAXX Vaxxinity Inc |
- -% |
0.00 | - | - | 4604.90 | 0.01 | 1898.03 | -1.98 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Louis Garfield Reese IV | Co-Founder & Exec. Chairman | 1983 |
| Ms. Mei Mei Hu J.D. | CEO & Director | 1984 |
| Dr. Ulo Palm M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. Jason Pesile CPA, M.B.A. | Sr. VP of Fin. & Accounting | 1973 |
| Mr. Dwayne Soisson | VP of Operations | NA |
| Mr. Benjamin Matone | VP of Investor Relations | NA |
| Mr. Rene Paula Molina | Gen. Counsel & Sec. | 1979 |
| Mr. Jon Harrison | Chief Gov. Officer | NA |
| Mr. Mark Joinnides | Chief of Staff | NA |
| Ms. Amy B. Fix M.B.A., M.S., R.A.C. | Chief Regulatory Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.